
|Videos|March 1, 2017
Impact of a Value-Based Formulary in Three Chronic Disease Cohorts
Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Advertisement
Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
2
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
3
Counseling Vitiligo Patients on Time to Repigmentation
4
5 August FDA Approvals Marked by Novelty, Pushback
5




